Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Summary
RATIONALE: A donor peripheral stem cell transplant helps stop the growth of cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Once the donated stem cells begin working, the patient's immune system may see the remaining cancer cells as not belonging in the patient's body and destroy them. Giving an infusion of donor T cells may helps stop the patient's immune system from rejecting the donor's stem cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of donor T cells in treating patients with high-risk hematologic cancer who are undergoing donor peripheral blood stem cell transplant. Note: Only Phase I portion of study was performed. Due to slow accrual, study was closed before Phase II portion of study.
Timeline
- Start
- 2008-06
- Primary completion
- 2010-04
- Completion
- 2010-04
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD4+CD25+ regulatory T cells | Unknown | 3e+06 cells/kg | Intravenous |
| Subject | CD4+CD25+ regulatory T cells | Unknown | 1e+07 cells/kg | Intravenous |
| Subject | CD4+CD25+ regulatory T cells | Unknown | 3e+07 cells/kg | Intravenous |